Real-World Effectiveness of Dupilumab vs Omalizumab, Benralizumab, and Mepolizumab on Lung Function Improvement in Severe Asthma Patients: Findings from the EU-ADVANTAGE Study

Article de revue

Avec comité de lecture

Arnaud Bourdin, G. Canonica, Johann Virchow, Kinga Borsos, Richard Stanford, Olivier Ledanois, Jason Kwah, Wenzhen Ge, Lynn Huynh, Mei Duh, …

Journal of allergy and clinical immunology, Vol.155(2), pp.AB234-AB234

02/2025

Indicateurs

1 Consultations de la notice

Titre: Real-World Effectiveness of Dupilumab vs Omalizumab, Benralizumab, and Mepolizumab on Lung Function Improvement in Severe Asthma Patients: Findings from the EU-ADVANTAGE Study
Créateurs - sans rôle: Arnaud Bourdin - Inserm
G. Canonica - Humanitas University
Johann Virchow - Universitätsmedizin Rostock
Kinga Borsos - Sanofi, Cambridge, MA, USA
Richard Stanford - AESARA Inc., Chapel Hill, NC, USA
Olivier Ledanois - Sanofi, Paris, France
Jason Kwah - Regeneron Pharmaceuticals, Inc., Sleepy Hollow, NY, USA
Wenzhen Ge - Regeneron Pharmaceuticals, Inc., Sleepy Hollow, NY, USA
Lynn Huynh - Analysis Group
Mei Duh - Analysis Group
Andra Boca - Analysis Group, Inc., Boston, MA, USA
Wei-Han Cheng - Sanofi, Cambridge, MA, USA
Détails de publication: Journal of allergy and clinical immunology, Vol.155(2), pp.AB234-AB234
Éditeur: Elsevier Inc
Identifiants: 99158770909311
Unité académique: Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExp
Langue: English
Type de ressource: Journal article